|
|
|
International Clinical Trials
|
Case
studies provide real insight in how to choose comparators for rare
diseases and oncology studies. Drug development is a very complex, long,
and expensive process. Once a suitable molecule is identified, then
clinical trials are undertaken to establish the effect of an
intervention.
Treatment effects are
efficiently isolated by controlling for bias, and confounding and
minimising variation. Key features of clinical trials that are used to
meet this objective are randomisation (possibly with stratification),
adherence to intent-to-treat principles, blinding, prospective
evaluation, and use of a control group. Compared to other types of study
designs (e.g., casecontrol studies, cohort studies, and case reports),
randomised trials have high validity, but are more difficult and
expensive to conduct.
The gold standard of
any scientific evidence is data generated from a randomised control
trial. In these studies, a pool of patients is randomly assigned to two
groups that receive different treatment. An experimental group will
receive the investigational medicinal product (IMP) and a control group
can receive a range of different interventions. The most commonly
utilised are a placebo (an inert compound that has no effect on the
endpoints measured) and an active comparator (usually the standard of
care [SOC]) for the indication being tested for. The choice of
medication for the control group depends on the nature of the disease.
For example, oncology patients are always put on medication for ethical
reasons.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
About the author
Dr Vanessa Dekou, Managing Director, Clinical Services International (CSI) has extensive experience in drug development from preclinical to registration and commercialisation strategies and has secured product registration for several orphans and first-in-class drugs. She has successfully designed and executed numerous trials all over the world. As such, Vanessa understands all the challenges and requirements of supplying comparators to clinical trials and ensuring trials are delivered on time and on budget. Vanessa has worked with some of the largest biopharmaceutical and biotechnology companies to provide innovative solutions. At CSI, Vanessa is responsible for providing bespoke solutions to their clients to ensure comparator sourcing is not a rate-limiting step in the successful delivery of trials. She also works closely with pharma manufacturers to safeguard the supply chain and remain on the front line of advances in drug development. Vanessa has a PhD in Cardiovascular Genetics from University College of London, UK, an MBA from Cambridge, UK and a Masters in Market Access from University of Lyon, France.
|
|
|
|
|
|
 |
News and Press Releases |
 |
CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
PE overhang to fuel CDMO valuations and expansions, while VC overhang
will fuel continued demand for services in spite of adverse global
conditions
More info >> |
|
 |
White Papers |
 |
|
Modifying MDI Canister Surfaces to Improve Drug Stability & Drug Delivery
Presspart Manufacturing Ltd
Hydrofluoroalkane (HFA)-based propellants are widely used in modern metered-dose inhalers (MDIs), due to their lack hazardous and environmentally-damaging effects. However, an HFA's active pharmaceutical ingredient can interact with the canister substrate, causing deposition of the drug to the canister walls, or interact with the solution, causing degradation and resulting in increased impurity levels. Over the past few years, a number of surface coatings have been developed that can be applied to MDI canisters and valve components, to protect the contents from deposition and degradation. More recently, plasma processes have been developed to modify and improve the surface energy performance of a MDI canister. This approach has a number of advantages to alternative coatings but requires careful optimisation to ensure the highest quality finish and MDI performance. Richard Turner, Business Development Director, Presspart Manufacturing Ltd, explains.
More info >> |
|
|
